Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
Public ClinicalTrials.gov record NCT04142437. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the decision to treat their disease with VITRAKVI has been made by their treating physicians. During the study, patients' medical information such as treatment information with VITRAKVI, other medication or treatments, changes in disease status and other health signs and symptoms will be collected within the normal medical care by the treating doctor. Participants will be observed over a period from 24 to 60 months.
Study identification
- NCT ID
- NCT04142437
- Recruitment status
- Active, not recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 54 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 3, 2020 (Actual)
- Primary completion
- Dec 31, 2029 (Estimated)
- Completion
- Aug 1, 2030 (Estimated)
- Last update posted
- Oct 22, 2026
2020 – 2030
United States locations
- U.S. sites
- 33
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Research Inst. | Los Angeles | California | 90027 | — |
| UCLA - Mattel Children's Hospital | Los Angeles | California | 90095 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 82663 | — |
| Stanford Univ Med Ctr. / Lucile Packard Children's Hosp | Palo Alto | California | 94304 | — |
| Providence Health System - Southern California | Santa Monica | California | 90404 | — |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Torrance | California | 90502 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| University of Miami | Miami | Florida | 33146 | — |
| Nicklaus Children's Hospital | Miami | Florida | 33155 | — |
| Fort Wayne Medical Oncology Hematology | Fort Wayne | Indiana | 46804 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Maine Health | South Portland | Maine | 04106 | — |
| Johns Hopkins / Sidney Kimmel Cancer Center | Baltimore | Maryland | 21205 | — |
| Frederick Health-James M Stockman Cancer Institute | Frederick | Maryland | 21702 | — |
| Tufts / Neely Cancer Center | Boston | Massachusetts | 02111 | — |
| Detroit Clinical Research Center | Farmington Hills | Michigan | 48334 | — |
| Sparrow Cancer Center | Lansing | Michigan | 48912 | — |
| Nevada Cancer Research Foundation | Las Vegas | Nevada | 89169 | — |
| Great Lakes Cancer Center | Buffalo | New York | 14210 | — |
| Memorial Sloan Kettering Children's Cancer Center | New York | New York | 10065 | — |
| East Carolina University / Vidant Health | Greenville | North Carolina | 27834 | — |
| Mercy Health Youngstown | Youngstown | Ohio | 44501 | — |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15212 | — |
| Medical Univ. of South Carolina | Charleston | South Carolina | 29425 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| UT Southwestern Medical Center / Children's Health | Dallas | Texas | 75390 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Univ. of Utah / Huntsman Cancer Center | Salt Lake City | Utah | 84112 | — |
| Seattle Children's | Seattle | Washington | 98105 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
| Gundersen Health System | La Crosse | Wisconsin | 54601 | — |
| SSM Health Cancer Center - Dean Medical Group | Madison | Wisconsin | 53717 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04142437, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04142437 live on ClinicalTrials.gov.